Management of Polycystic Ovary Syndrome (PCOS)

Diagnostic Criteria

The American College of Obstetricians and Gynecologists recommends laboratory evaluation for PCOS diagnosis, including androgen levels and gonadotropins (LH, FSH) 1, 2
Screening for metabolic abnormalities, such as fasting glucose and lipid profile, is essential for PCOS diagnosis and management 3, 2
The American Family Physician suggests calculating body mass index and waist-hip ratio to assess metabolic risk 3

Treatment Approach Based on Reproductive Goals

The American College of Obstetricians and Gynecologists recommends combined oral contraceptives as first-line treatment for women with PCOS not attempting to conceive, which suppress ovarian androgen secretion and increase sex hormone binding globulin 4, 1, 3
For women with PCOS attempting to conceive, clomiphene citrate is the first-line pharmacological treatment, with approximately 80% of patients ovulating and half conceiving 3
The American Family Physician suggests low-dose gonadotropin therapy if clomiphene treatment fails, due to lower risk of ovarian hyperstimulation 3, 1

Management of Metabolic Aspects

Lifestyle modifications, including weight loss and regular exercise, are the cornerstone of PCOS treatment, with a recommended energy deficit of 30% or 500-750 kcal/day 1, 3
The American Diabetes Association recommends metformin to improve insulin sensitivity and reduce risk factors for diabetes and cardiovascular disease 3, 4
The American Heart Association suggests regular screening for metabolic abnormalities, including type 2 diabetes mellitus and cardiovascular disease, due to increased risk in PCOS patients 3, 4

Long-term Monitoring and Complications

The American College of Obstetricians and Gynecologists recommends regular screening for metabolic abnormalities and mental health assessment, as women with PCOS have higher rates of depression, anxiety, and eating disorders 1, 3
The American Family Physician suggests avoiding exceeding recommended clomiphene dosage and duration, and not neglecting metabolic screening even in normal-weight PCOS patients 3, 1

Lifestyle Modification and Treatment for Polycystic Ovary Syndrome (PCOS)

Introduction to PCOS Management

Lifestyle modification targeting 5-10% weight loss through diet and exercise is the foundational first-line treatment for all women with PCOS, improving metabolic, reproductive, and psychological outcomes 5, 6, 7

Core Lifestyle Intervention Components

Target an energy deficit of 500-750 kcal/day, with a total intake of 1,200-1,500 kcal/day, adjusted for individual energy requirements, body weight, and physical activity levels 8
Any balanced dietary approach that creates an energy deficit is acceptable, with no evidence that any specific diet type is superior in PCOS compared to general population recommendations 8
Follow general healthy eating principles, tailoring to food preferences while avoiding overly restrictive or nutritionally unbalanced diets 8
For weight maintenance and health, perform at least 150 minutes/week of moderate-intensity activity or 75 minutes/week of vigorous activity, plus muscle-strengthening activities on 2 non-consecutive days/week 8
For weight loss and prevention of regain, perform at least 250 minutes/week of moderate-intensity activity or 150 minutes/week of vigorous activity, plus muscle strengthening on 2 non-consecutive days/week 8
Incorporate goal-setting, self-monitoring, stimulus control, problem-solving, assertiveness training, slower eating, reinforcement of changes, and relapse prevention to optimize weight management and emotional well-being 8
Recognize that ethnic groups at high cardiometabolic risk require greater consideration for lifestyle intervention, and ethnic-specific BMI and waist circumference categories should guide treatment intensity 8

Emerging and Adjunctive Therapies

GLP-1 agonists, such as semaglutide, liraglutide, and exenatide, show promise for weight reduction and metabolic improvement in PCOS when combined with lifestyle interventions 9

Treatment of PCOS with Insulin Resistance

First-Line Treatment: Structured Lifestyle Intervention

The American College of Cardiology recommends a multicomponent lifestyle intervention, combining diet, exercise, and behavioral strategies, as the mandatory first-line treatment for all patients with PCOS and insulin resistance, regardless of body weight 10
A balanced dietary approach that creates an energy deficit of 500-750 kcal/day is acceptable, with no specific diet type proven superior in PCOS, and general healthy eating principles should be followed 11

Second-Line Treatment: Pharmacological Management

The American Academy of Family Physicians recommends adding metformin (500-2000 mg daily) when insulin resistance or glucose intolerance is documented, lifestyle modifications alone are insufficient for metabolic control, or the patient has obesity or elevated cardiovascular risk factors 12
The American Academy of Family Physicians suggests that combined oral contraceptives (COCs) are first-line hormonal therapy for women not attempting to conceive, as they suppress ovarian androgen secretion, increase sex hormone-binding globulin, regulate menstrual cycles, prevent endometrial hyperplasia, and reduce hirsutism and acne 12

Emerging Anti-Obesity Agents

The international evidence-based guideline systematic review found that GLP-1 receptor agonists (liraglutide, semaglutide, exenatide) and orlistat show promise for weight reduction and metabolic improvement when combined with lifestyle interventions, with liraglutide, semaglutide, and orlistat appearing superior to placebo for anthropometric outcomes 10, 13

Mandatory Metabolic Screening

The American College of Cardiology recommends comprehensive metabolic surveillance for all patients with PCOS, regardless of weight, including screening for type 2 diabetes, fasting lipid profile, calculation of BMI and waist-hip ratio, and repeat screening at least annually 12, 14
The American College of Cardiology suggests using ethnic-specific BMI and waist circumference categories to guide treatment decisions, particularly for ethnic groups with PCOS who are at high cardiometabolic risk (Asian, Hispanic, South Asian) 14

Evidence‑Based Recommendations for Managing Pregnancy in Women with Polycystic Ovary Syndrome

Preconception and Early Pregnancy Assessment

Blood pressure, renal function, and thyroid function should be evaluated before conception to identify modifiable risk factors and guide early obstetric care. [Human Reproduction Update] 15

Weight and Lifestyle Management

A modest pre‑pregnancy weight loss of about 5 % is associated with improved metabolic and reproductive outcomes, supporting the goal of achieving a healthier baseline weight before conception. [American Family Physician] 16
A balanced pregnancy diet that meets caloric needs without aggressive restriction is recommended, helping to avoid excessive gestational weight gain while supporting fetal growth. [Circulation Research] 17
Gestational weight gain should be monitored according to the Institute of Medicine (IOM) guidelines, with targets adjusted for the woman’s pre‑pregnancy body‑mass index. [Circulation Research] 17

Pharmacological Considerations

Metformin

Metformin is considered safe for use during pregnancy according to the American College of Obstetricians and Gynecologists (ACOG) guidelines, although current evidence does not support its routine use solely for preventing gestational diabetes or preeclampsia in PCOS. [American Family Physician] 16

Medications to Discontinue

Thiazolidinediones (e.g., rosiglitazone, pioglitazone) should be stopped before or during pregnancy because safety data are insufficient. [American Family Physician] 16
Clomiphene citrate should be discontinued once pregnancy is confirmed, as continued exposure offers no benefit and may pose risk. [American Family Physician] 16
Oral contraceptives must be avoided during pregnancy, consistent with standard obstetric practice. [American Family Physician] 16

Guidelines for Adding Spironolactone in Women with PCOS and Persistent Hyperandrogenic Manifestations

Indications for Adding Spironolactone

Spironolactone 50–100 mg daily should be added when a woman with polycystic ovary syndrome continues to have clinically significant hirsutism, acne, or androgenic alopecia after 3–6 months of optimal‑dose combined oral contraceptive (COC) therapy plus lifestyle modifications. 18
An adequate COC trial is defined as ≥3–6 months of a full‑dose COC (30–35 µg ethinyl estradiol with drospirenone, norgestimate, or levonorgestrel) before considering spironolactone. [19][18]
Persistent hyperandrogenic signs that warrant spironolactone include a Ferriman‑Gallwey score that remains bothersome, acne that markedly impairs quality of life, or progressive androgenic alopecia despite COC therapy. 18

Dosing and Duration

Starting dose: 50 mg daily is effective for most patients and offers better tolerability; 100 mg daily may be required for severe hirsutism. 18
Doses up to 200 mg daily have been studied but provide only marginal additional benefit and are not routinely recommended. 18
Clinical improvement in hirsutism, acne, and serum testosterone is typically observed by 6 months of combined therapy. 18

Safety of the COC + Spironolactone Combination

Studies demonstrate no clinically significant potassium elevation when spironolactone is combined with drospirenone‑containing COCs; the combination does not increase treatment‑discontinuing side effects. [19][18]

Pre‑Treatment Screening and Ongoing Monitoring

Baseline serum potassium should be measured before initiating spironolactone. 18
Effective contraception must be confirmed because spironolactone is teratogenic and can feminize male fetuses. 18
Potassium monitoring is required in patients who are older, have hypertension, diabetes, chronic kidney disease, or are taking ACE inhibitors, ARBs, or NSAIDs; it is not routinely required in young, healthy women without comorbidities or interacting medications. 18

Common Adverse Effects and Counseling Points

Menstrual irregularities/polymenorrhea occur in approximately 40–68 % of patients, especially those with classic PCOS phenotype. 18
Other possible side effects include breast tenderness, fatigue, headache, and dizziness; these are less frequent when spironolactone is used together with a COC. 18

Advantages of Combination Therapy (Spironolactone + COC)

COCs suppress ovarian androgen production and increase SHBG, while spironolactone blocks androgen receptors and inhibits peripheral testosterone synthesis; together they provide a synergistic reduction in androgenic activity. 18
The COC component mitigates menstrual irregularities caused by spironolactone, improving overall tolerability. 18
Combined therapy enhances patient compliance compared with either agent alone. 18

Critical Pitfalls to Avoid

Do not add spironolactone before 3 months of COC therapy unless hyperandrogenic symptoms are severely impairing quality of life. [19][18]
Never prescribe spironolactone without confirmed effective contraception due to teratogenic risk. 18
Routine potassium monitoring is unnecessary in young, healthy PCOS women without comorbidities or interacting drugs. 18
Do not discontinue the COC when spironolactone is added; maintaining both agents yields superior efficacy and tolerability. 18

Monitoring Androgen Levels in Lean PCOS Patients

Laboratory Assessment

Measure total testosterone, free testosterone, and sex‑hormone‑binding globulin (SHBG) at baseline and after a minimum of 6 months of combined myo‑inositol + D‑chiro‑inositol therapy to evaluate androgen response; use liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) when available for accurate quantification. 20

Management of Spironolactone Use in Women with PCOS Planning Pregnancy

Teratogenic Risk and Reversibility

Spironolactone should be discontinued before attempting conception because it is classified as pregnancy category C and carries a teratogenic risk (including potential feminization of male fetuses), yet it does not cause permanent impairment of ovarian function or fertility. 21

Lifestyle Modification and First‑Line Pharmacotherapy for Fertility in PCOS

Mandatory Structured Lifestyle Modification

All women with polycystic ovary syndrome (PCOS) who are trying to conceive should start with a structured lifestyle‑modification program—regardless of body‑mass index—because it improves metabolic health, reproductive function, and psychological wellbeing, and is placed at the top of the treatment hierarchy. 22
Metabolic benefits of lifestyle modification occur even in normal‑weight women with PCOS; therefore, the program should not be omitted based on BMI alone. 22

Impact of Modest Weight Loss

Achieving a modest weight loss of approximately 5 % of body weight in overweight women with PCOS leads to measurable improvements in ovulation frequency and pregnancy rates. 23